Funding for this research was provided by:
Rare Diseases Clinical Research Network (U54 AR068069)
National Institute of Child Health and Human Development (P50HD103555)
National Institute of Dental and Craniofacial Research (R01 DE031162, R01 DE031288)
National Heart, Lung, and Blood Institute (T32 HL092332)
Lawrence Family Bone Disease Program of Texas
Article History
Accepted: 23 March 2024
First Online: 11 April 2024
Declarations
:
: EB and SCSN declare no competing interests. BL reports non-financial support and other from Baylor Genetics Laboratory, personal fees from Biomarin, other from Acer Therapeutics, other from Sanofi, and other from GQ Bio Therapeutics during the conduct of the study; grants from Sanofi, grants from Kirin Kyowa outside the submitted work.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The mention of trade names, commercial products, or organizations does not imply endorsement by the USA Government.